Human monoclonal antibodies to epidermal growth factor receptor

Details Human monoclonal antibodies to epidermal growth factor receptor Human monoclonal antibodies to epidermal growth factor receptor

2005-11-04

2010-10-05

Wehbe, Anne Marie S (Department: 1633)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388220

Reexamination Certificate

active

07807798

ABSTRACT:
In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.

REFERENCES:
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6657103 (2003-12-01), Kucherlapati et al.
patent: 6713610 (2004-03-01), Kucherlapati et al.
patent: 2003/0070185 (2003-04-01), Jakobovits et al.
patent: 586 002 (1993-08-01), None
patent: 712 863 (1996-05-01), None
patent: WO 91/00906 (1991-01-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 02/076406 (2002-10-01), None
Li et al. (1996) J. Mol. Biol., vol. 256, 577-589.
Defize et al. (1989), J. Cell. Biol. vol. 109, pp. 2495-2507.
Bruns et al. (2000) Canc. Res., vol. 60, 2926-2935.
Sunada et al. (1990) J. Cell. Physiol., vol. 142, 284-292.
Reins et al. (1993) J. Cell. Biochem., vol. 51, 236-248.
Office Action dated Oct. 21, 2005, for U.S. Appl. No. 10/978,290, filed Oct. 29, 2004.
Office Action dated Oct. 24, 2005, for U.S. Appl. No. 10/978,297, filed Oct. 29, 2004.
Weber et al., “Immunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylation,”JBC, 259:14631-14636 (1984).
Yarden et al., “Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies,”JBC, 260:315-319 (1985).
Amendment and Response dated Apr. 19, 2006, for U.S. Appl. No. 10/978,297, filed Oct. 29, 2004.
Office Action mailed Jul. 12, 2006, for U.S. Appl. No. 10/978,297, filed Oct. 29, 2004.
Aboud-Pirak et al., Dec. 21, 1988, “Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma in Vitro and in Nude Mice.” J. Nat'l Cancer Inst. 80: 1605-1611.
Aboud-Pirak et al., 1988, “Monoclonal Anti EGF Receptor Antibodies Inhibit the Growth of Tumor Cells in Nude Mice.” J. Cell. Biochem. Supp. 12A: 137.
Baselga et al., 1994, “Receptor Blockade With Monoclonal Antibodies as Anti-Cancer Therapy.” Pharmac. Ther. 64: 127-154.
Bruggemann, M. et al., Sep. 1989, “A repertoire of monoclonal antibodies with human heavy chains from transgenic mice.” Proceedings of the National Academy of Sciences USA 86: 6709-6713.
Bruggemann, M. et al., 1990, “Construction, Function and Immunogenicity of Recombinant Monoclonal Antibodies.” Behring Inst. Mitt. 87: 21-24.
Bruggemann, M. et al., 1991, “Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus.” Eur. J. Immunol. 21: 1323-1326.
Bruggemann, M. et al., Aug. 1996, “Strategies for expressing human antibody repertoires in transgenic mice.” Immunology Today 17: 391-397.
Buttin, G., Aug. 1987, “Exogenous Ig gene rearrangement in transgenic mice: a new strategy for human monoclonal antibody production?” Trends in Genetics 3: 205-206.
Corvalan et al., Jan. 1, 1997, “Generation of fully human high affinity monoclonal antibodies to EGF receptor in mice,” The Journal of Allergy and Clinical Immunology, 99(1, part 2, supp.): s15.
Defize et al., Nov. 1989, “Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors,” J. Cell Biology, 109(5): 2495-2507.
Ennis et al., Nov. 1989, “Anti-Epidermal Growth Factor Receptor Antibodies Inhibit the Autocrine-Stimulated Growth of MDA-468 Human Breast Cancer Cells.” Molec. Endocrinol. 3: 1830-1838.
Fendly et al., Mar. 1, 1990, “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
euGene Product.” Cancer Res. 50: 1550-1558.
Fishwild, D.M. et al., Jul. 1996, “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice.” Nature Biotechnology 14: 845-851.
Fong et al., Nov. 1, 1992, “Epidermal Growth Factor Receptor Monoclonal Antibody Inhibits Constitutive Receptor Phosphorylation, Reduces Autonomous Growth, and Sensitizes Androgen-independent Prostatic Carcinoma Cells to Tumor Necrosis Factor α.” Cancer Res. 52: 5887-5892.
GenBank Accession No. Z70619,H. sapiensmRNA for immunoglobulin heavy chain variable regions (6D4-A5, VH4, 4-31/DP-65), accessed Dec. 3, 1998 (1996).
GenBank Accession No. Z70658,H. sapiensmRNA for immunoglobulin heavy chain variable regions (83-6H3, VH4, 4-61/DP-66), accessed Dec. 3, 1998 (1996).
Gill et al., Jun. 25, 1984, “Monoclonal Anti-epidermal Growth Factor Receptor Antibodies Which Are Inhibitors of Epidermal Growth Factor Binding and Antagonists of Epidermal Growth Factor-stimulated Tyrosine Protein Kinase Activity.” J. Biol. Chem. 259: 7755-7760.
Green, L.L., et al., May 1994, “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs.” Nature Genetics 7: 13-21.
Jakobovits, A., 1995, “Production of fully human antibodies by transgenic mice.” Curr. Opin. Biotechnol. 6: 561-566.
Jakobovits, A., et al., 1995, “Production of Antigen-Specific Human Antibodies from Mice Engineered with Human Heavy and Light Chain YACs.” Annals New York Academy of Sciences 764: 525-535.
Jakobovits, A., et al., 1997, “Humoral immunity in mice engineered with megabase human heavy and kappa light chain YACs.” J. Allergy Clin. Immunol. 99: S113.
Jakobovits et al., Jan., 1997, “Humoral immunity in mice engineered with megabase human heavy and kappa light chain YACs,” The Journal of Allergy and Clinical Immunology, 99(1, part 2, supp.): s113.
Jakobovits et al., Apr. 6, 1998, “Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci,” Advanced Drug Delivery Reviews, 31(1-2): 33-42.
Jakobovits, Apr. 1998, “The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice,” Expert Opinion on Investigational Drugs, 7(4): 607-614.
Klein, 1982,Immunology: The Science of Self-Nonself Discrimination, John Wiley & Sons: New York, NY pp. 176-183.
Lonberg, N. et al., Apr. 28, 1994, “Antigen-specific human antibodies from mice comprising four distinct genetic modifications.” Nature 368: 856-859.
Masui et al., Mar. 1984, “Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies.” Cancer Res. 44: 1002-1007.
Masui et al., Nov. 1986, “Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes.” Cancer Res. 46: 5592-5598.
Matsumoto et al., Mar. 1997,

Affiliated with

Also associated with

Rating

Human monoclonal antibodies to epidermal growth factor receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibodies to epidermal growth factor receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to epidermal growth factor receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4193332